Evidence map›Paper›PMID 30809319›Full record

ArticleDisease markers2019

The Dynamic Use of

Mónica Macías, Estibaliz Alegre, Gorka Alkorta-Aranburu, Ana Patiño-García, Beatriz Mateos, Maria P Andueza, Alfonso Gúrpide, Jose M Lopez-Picazo, Ignacio Gil-Bazo, Jose L Perez-Gracia and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Disease markers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Mónica MacíasService of Biochemistry, Clínica Universidad de Navarra, Av. Pio XII 36 Pamplona 31008, Spain.
Estibaliz AlegreService of Biochemistry, Clínica Universidad de Navarra, Av. Pio XII 36 Pamplona 31008, Spain.ORCID 0000-0002-9053-3606
Gorka Alkorta-AranburuUnit of Genomics, CIMA LAB Diagnostics, University of Navarra, Av. Pio XII 55 31008 Pamplona, Spain.
Ana Patiño-GarcíaNavarra Institute for Health Research (IdiSNA), c/ Irunlarrea 3 31008 Pamplona, Spain.
Beatriz MateosService of Biochemistry, Clínica Universidad de Navarra, Av. Pio XII 36 Pamplona 31008, Spain.
Maria P AnduezaDepartment of Oncology, Clínica Universidad de Navarra, Av. Pio XII 36 31008 Pamplona, Spain.
Alfonso GúrpideNavarra Institute for Health Research (IdiSNA), c/ Irunlarrea 3 31008 Pamplona, Spain.
Jose M Lopez-PicazoNavarra Institute for Health Research (IdiSNA), c/ Irunlarrea 3 31008 Pamplona, Spain.
Ignacio Gil-BazoNavarra Institute for Health Research (IdiSNA), c/ Irunlarrea 3 31008 Pamplona, Spain.
Jose L Perez-GraciaNavarra Institute for Health Research (IdiSNA), c/ Irunlarrea 3 31008 Pamplona, Spain.
Álvaro GonzálezService of Biochemistry, Clínica Universidad de Navarra, Av. Pio XII 36 Pamplona 31008, Spain.ORCID 0000-0002-1423-273X
Navarre Institute of Health Research · ESClinica Universidad de Navarra · ESUniversidad de Navarra · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epidermal growth factor receptor (

Indexed as

MutationAgedAntineoplastic AgentsBiomarkers, TumorCarcinoma, Non-Small-Cell LungCell-Free Nucleic AcidsErbB ReceptorsFemaleHumansLung NeoplasmsMaleMiddle AgedProtein Kinase InhibitorsAntineoplastic AgentsBiomarkers, TumorCell-Free Nucleic AcidsEGFR protein, humanErbB ReceptorsProtein Kinase Inhibitors

Identifiers

PMID30809319
PMCPMC6364099
OpenAlexW2912838188

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.